Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P15088 (
mast cell
)
14,925
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have identified and characterized two mouse cDNAs in a mouse antigen-stimulated bone marrow-derived
mast cell
cDNA library, both of which encode type I transmembrane proteins. The genes were closely mapped in the distal region of mouse chromosome 11 and expressed not only in mast cells but also widely in leukocytes. The extracellular domains of their encoded proteins contain a single variable immunoglobulin (Ig) motif sharing about 90% identity with amino acids, showing that they comprise a pair of molecules and belong to the Ig superfamily. We named these molecules leukocyte mono-Ig-like receptor1 and 2 (
LMIR1
and 2). The intracellular domain of
LMIR1
contains several immunoreceptor tyrosine-based inhibition motifs (ITIMs). When cross-linked, the intracellular domain was tyrosine phosphorylated and capable of recruiting tyrosine phosphatases, SHP-1 and SHP-2 and inositol polyphosphate 5-phosphatase, SHIP. LMIR2, on the other hand, contains a short cytoplasmic tail and a characteristic transmembrane domain carrying two positively charged amino acids associated with three kinds of immunoreceptor tyrosine-based activation motif (ITAM)-bearing molecules, DAP10, DAP12, and FcRgamma. These findings suggest that a new pair of ITIM/ITAM-bearing receptors,
LMIR1
and 2, regulate
mast cell
-mediated inflammatory responses through yet to be defined ligand(s).
...
PMID:Identification and characterization of a new pair of immunoglobulin-like receptors LMIR1 and 2 derived from murine bone marrow-derived mast cells. 1289 83
Mast cell-mediated responses are likely to be regulated by the cross talk between activatory and inhibitory signals. We have screened human cord blood mast cells for recently characterized inhibitory receptors expressed on NK cells. We found that IRp60, an Ig superfamily member, is expressed on human mast cells. On NK cells, IRp60 cross-linking leads to the inhibition of cytotoxic activity vs target cells in vitro. IRp60 is constitutively expressed on mast cells but is down-regulated in vitro by the eosinophil proteins major basic protein and eosinophil-derived neurotoxin. An immune complex-mediated cross-linking of IRp60 led to inhibition of IgE-induced degranulation and stem cell factor-mediated survival via a mechanism involving tyrosine phosphorylation, phosphatase recruitment, and termination of cellular calcium influx. To evaluate the role of IRp60 in regulation of allergic responses in vivo, a murine model of allergic peritonitis was used in which the murine homolog of IRp60,
LMIR1
, was neutralized in BALB/c mice by mAbs. This neutralization led to a significantly augmented release of inflammatory mediators and eosinophilic infiltration. These data demonstrate a novel pathway for the regulation of human
mast cell
function and allergic responses, indicating IRp60 as a candidate target for future treatment of allergic and
mast cell
-associated diseases.
...
PMID:The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. 1633 35
LPS triggers inflammatory responses; however, the negative regulation of LPS responses
in vivo
remains poorly understood.
CD300f
is an inhibitory receptor among the CD300 family of paired activating and inhibitory receptors. We have previously identified ceramide as a ligand for
CD300f
and shown that the binding of ceramide to
CD300f
inhibits IgE-mediated
mast cell
activation and allergic responses in mouse models. Here we identify the critical role of
CD300f
in inhibiting LPS-induced skin inflammation.
CD300f
deficiency remarkably enhanced LPS-induced skin edema and neutrophil recruitment in mice. Higher levels of factors that increase vascular permeability and of factors that induce neutrophil recruitment were detected in LPS-injected skin pouch exudates of
CD300f
-/-
mice as compared with wild-type mice.
CD300f
was highly expressed in mast cells and recruited neutrophils, but not in macrophages, among skin myeloid cells.
CD300f
deficiency failed to influence the intrinsic migratory ability of neutrophils. Ceramide-
CD300f
binding suppressed the release of chemical mediators from mast cells and from neutrophils in response to LPS. Adoptive transfer experiments indicated that mast cells mediated enhanced edema in LPS-stimulated skin of
CD300f
-/-
mice, whereas mast cells together with recruited neutrophils mediated robust neutrophil accumulation. Importantly, administering a ceramide antibody or ceramide-containing vesicles enhanced or suppressed LPS-induced skin inflammation of wild-type mice, respectively. Thus, ceramide-
CD300f
binding inhibits LPS-induced skin inflammation, implicating
CD300f
as a negative regulator of Toll-like receptor 4 (TLR4) signaling
in vivo
.
...
PMID:Ceramide-CD300f Binding Inhibits Lipopolysaccharide-induced Skin Inflammation. 2807 16
Sepsis is a serious clinical problem. Negative regulation of innate immunity is associated with sepsis progression, but the underlying mechanisms remains unclear. Here we show that the receptor
CD300f
promotes disease progression in sepsis.
CD300f
-/-
mice were protected from death after cecal ligation and puncture (CLP), a murine model of septic peritonitis.
CD300f
was highly expressed in mast cells and recruited neutrophils in the peritoneal cavity. Analysis of mice (e.g.,
mast cell
-deficient mice) receiving transplants of wild-type or
CD300f
-/-
mast cells or neutrophils indicated that
CD300f
deficiency did not influence intrinsic migratory abilities of neutrophils, but enhanced neutrophil chemoattractant production (from mast cells and neutrophils) in the peritoneal cavity of CLP-operated mice, leading to robust accumulation of neutrophils which efficiently eliminated Escherichia coli. Ceramide-
CD300f
interaction suppressed the release of neutrophil chemoattractants from Escherichia coli-stimulated mast cells and neutrophils. Administration of the reagents that disrupted the ceramide-
CD300f
interaction prevented CLP-induced sepsis by stimulating neutrophil recruitment, whereas that of ceramide-containing vesicles aggravated sepsis. Extracellular concentrations of ceramides increased in the peritoneal cavity after CLP, suggesting a possible role of extracellular ceramides,
CD300f
ligands, in the negative-feedback suppression of innate immune responses. Thus,
CD300f
is an attractive target for the treatment of sepsis.
...
PMID:Disrupting ceramide-CD300f interaction prevents septic peritonitis by stimulating neutrophil recruitment. 2865 92